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Abstract
The prostate is an accessory gland of the male reproductive tract, and its presence is
universal in mammals. It is committed to the prostatic fluid production and storage,
which is released with other semen components during ejaculation. Such fluid contributes
to increasing motility and fertility of the spermatozoa, and the neutralization of the
vagina, thus playing an important role in fertilization. Few pathological complications,
often progressively aggravated with age, can affect this gland (i.e. benign and malignant
proliferative changes; all to be described next in this chapter). Nowadays, the neoplastic
expansion is the main motivator and contributor for studies on enlightening of growth
regulation mechanisms and physiology of the prostate.
Keywords: physiology, pathology, benign prostatic hyperplasia, prostate cancer,
biomarkers
1. Prostate anatomy
The human prostate is a pelvic gland located under the urinary bladder and in front of the
rectum, and it is composed by glandular and non-glandular structures surrounded by one
same capsule [1–3]. It consists mainly of muscular-fibrous tissue, which it is subdivided into
about 50 tubule-alveolar glands [4], at the lateral and posterior segment of the urethra, which
drain to 20–30 small prostatic ductules opening in the prostate, or close to the posterior wall of
the prostatic urethra [5–8]. The prostatic secretion, which accounts for approximately 20% of
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the seminal fluid, confers a characteristic odor of this flowing, and participates in the activation
of spermatozoa [8]. The ducts of the prostatic glands open into a sulcus located on each side of
the urethral ridge, called the prostatic sinus. The prostate is traversed throughout the prostatic
portion of the urethra, from the base to the apex, with a slightly curved course in the anterior-
posterior direction, and closer to its anterior face [5–8].
The prostate is anatomically described as an inverted pyramid whose apex is the lowest
portion, and which is located about 1.5 cm behind the lower border of the pubic symphysis
and is directly related to the upper face of the urogenital diaphragm. The base of the prostate
gland is in a horizontal plane that passes through the middle part of the pubic symphysis, and
it is directly related to the cervix of the bladder and the inner ostium of the urethra. Inferior-
lateral surfaces are convex and are separated from the superior fascia of the pelvic diaphragm
by a venous plexus, and are related to the pubococcygeal muscles [6–9]. The posterior surface
is flattened and triangular, and it is related to the bladder of the rectum. The anterior surface is
narrow and separated from the pubic symphysis by retropubic fat tissue. The upper part is
related to the seminal glands and to the lower extremities of the vas deferens, and near its base
presents small depressions for the entrance of the ejaculatory ducts [6].
Despite not being clearly distinguished anatomically, the following prostate lobes are tradi-
tionally defined: right, left and a middle lobe [5–8]. In pathology, the prostate is described in
different zones (peripheral zone, central zone, transition zone and anterior fibro-muscular
zone) [9]. The right and left lobes are not isolated from each other, being connected, prior to
the urethra, by the isthmus of the prostate, constituted by fibromuscular tissue. Their muscular
fibers represent the superior continuation of the external sphincter muscle of the urethra to the
cervix of the bladder, and it is devoid of glandular tissue. The middle lobe, of variable size, is
the part of the prostate that protrudes internally from the upper part of the posterior face of the
organ, between the ejaculatory duct and the urethra [5–8]. However, structurally, the middle
lobe is indeed inseparable from the right and left lobes. In each prostate lobe we can identify
four lobules: (I) Posterior-Inferior, located posterior to the urethra, and inferior to the ejacula-
tory ducts. It constitutes the face of the prostate, palpable to digital rectal examination; (II)
Lateral-Inferior, directly lateral to the urethra, forming the major part of the right or left lobe;
(III) Superomedial, deeply to the inferoposterior lobe, surrounding the ipsilateral ejaculatory
duct; (IV) Anteromedial, deeply to the inferolateral lobe, directly lateral to the proximal
portion of the prostatic urethra.
The superior fascia of the pelvic diaphragm reflects in the superior direction from the visceral
fascia of the pelvis to envelop the prostate, and then continues superiorly over the bladder. The
portion covering the prostate is dense and fibrous, being called the fascia of the prostate. It is
located externally to the prostate capsule and is separated from it, laterally and anteriorly, by
the loose connective tissue harboring the prostatic venous plexus. The fascia of the prostate
fuses anteriorly with the tendinous arch of the pelvic fascia, which at the level of the pube is
called the medial puboprostatic ligament [5–7]. Smooth muscle fibers fulfill this ligament, and
it is called the puboprostatic muscle. The lateral puboprostatic ligament extends from the
fascia of the prostate to the tendon arch of the pelvic fascia. Inferior to the puboprostatic
ligaments, the prostate associates with the medial borders of the pubococcygeus muscle, and
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from this point the muscle fibers extend in the superior direction to fuse with the fascia of the
prostate, forming the prostate lifting muscle. Later, the fascia of the prostate is separated from
the tunica of the rectum by the rectovesical septum [6, 10].
The prostatic arteries are usually direct branches of the inferior bladder artery from one of the
branches of the internal iliac artery. In some cases, it may be a branch of the internal pudendal
artery, or the medial rectal artery [5–7, 10]. The veins draining the prostate girdle, to form the
prostatic venous plexus, located in the fascia of the prostate. The prostatic venous plexus
continuous superiorly with the bladder venous plexus, and communicates posteriorly with
the internal vertebral venous plexus. The lymphatic vessels of the prostate drain into the
internal iliac lymph nodes [5–7, 10]. Finally, the prostate is innervated by sympathetic fibers
from the lower hypogastric plexus. These fibers innervate smooth muscle fibers and blood
vessels [5–7, 10].
2. Prostate gland hormonal regulation
There are considerable variations related to the prostate anatomy, biochemistry and pathology
of several mammal species. In humans, the sexual accessory tissues (or glands) produce high
concentration of several biologically active substances, such as fructose, citric acid, spermine,
prostaglandins, zinc, proteins including immunoglobulins, and specific enzymes (i.e. esterases
and phosphatases) [11].
The growth, differentiation and maintenance of the activity of the prostate gland [12] are
mainly controlled by androgens, which is the basis of the anti-androgenic therapies for the
treatment of primary prostate cancer. The development and physiology of the prostate is also
directly modulated by somatothrophic hormones (such as insulin, prolactin and growth hor-
mone), retinoic acid and estrogen [13, 14], as well as a biomolecular scenario of complex
interactions between the epithelium and stroma [15], which sum up to a complicated and
poorly understood regulatory mechanism.
Receptors type androgen receptor (AR) and estrogen receptor (ER) are responsible for mediat-
ing the physiological effects of androgens and estrogens, respectively [16, 17]. Briefly, the
receptor located in the cytoplasm binds to testosterone or dihydrotestosterone, dissociates a
heat shock protein (HSP), dimerizes, and it is translocated to the nucleus, where, together with
a variety of co-activators and co-repressors, activates or inactivates different sets of genes [18].
The classic AR has 110 kDa and several features in common with members of the nuclear
receptor family, such as estrogen receptors, progesterone, thyroid hormones, and peroxisome
proliferator-activated receptors (PPARs) [19].
Testosterone and dihydrotestosterone (DHT) act through AR. The AR primarily functions as a
transcription factor. It is an extremely important molecule, responsible for the primary male
sex differentiation (formation of gonads and external genitalia), and for the pubertal acquisi-
tion of the male secondary characteristics (events associated with puberty and adolescence)
[20]. It is also liable for most cases of complete androgen insensitivity (resulting in infertile XY
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karyotype female) [21], and it is deeply associated with the origin of prostate tumors and,
particularly, with the recurrence of androgen independent cancer [22–24].
The most striking androgen dependence of the prostate gland is observed by hormonal or
surgical castration. In a rat model, removal of the testes results in prostate involution to
approximately 10% of its original size after 21 days. Epithelial cells death and stroma reorga-
nization are responsible by such event [25]. Similar to AR, estrogen receptors (ERs) belong to
the family of nuclear receptors. The two subtypes, ERα and ERβ, have different physiological
roles. They share homology with each other, but are the products of different genes [26]. Both
ERα and ERβ are expressed in the prostate. In adults, ERα and ERβ are preferentially found in
the stroma and in the epithelium, respectively [27]. Similarly to the AR, ER expression might
be suppressed by methylation of its promoters, and this epigenetic alteration was suggested to
be involved in both benign prostatic hyperplasia and prostate cancer development [28, 33].
The action of estrogens on prostatic ductal morphogenesis and cell differentiation is complex
[14]. However, a brief exposure of rodents to estrogens during neonatal development causes
irreversible and dose-dependent effects on morphology, cellular organization and function of
the gland [29, 30]. Reduced prostate size at adulthood was associated with decreased respon-
siveness at puberty due to reduced AR content [31]. The reduced AR levels were justified by
increased proteasomal degradation of AR protein at postnatal day 10 [32].
Estrogen exposure to occasional doses during the gestation period causes increased concentra-
tions of androgen receptor in mice, ductal budding and prostate weight later in the adulthood
[34]; whereas the neonatal exposure to high doses compromises the growth epithelial differen-
tiation, and accounts for changes in the secretory function, as well as for incidence of prostatic
intraepithelial neoplasia (PIN) and prostatitis [14, 29]. The effect of high doses of estrogens on
the neonatal prostate is due not only to the changes in the androgen concentrations, via
permanent actions on the hypothalamic-gonadal pituitary gland, but also due to direct effects
on the prostate gland, since the administration of testosterone is not able to reverse those
effects [35]; this phenomena is known as estrogenic imprinting.
High doses of estrogen administered in adult animals function as castration, resulting in the
inhibition of the hypothalamic-pituitary-gonadal axis, by suppression of the gonadotrophin
releasing hormone, and consequent blockage of the hormone testosterone by the testes [36, 37].
Nonetheless, such effects can be reversed (contrary to those observed in neonates), by
replacing testosterone or dihydrotestosterone hormones.
It is well established that some of the circulating androgens are converted into estrogens in
various peripheral tissues by the enzyme aromatase [38]. The aromatase was also identified in
the human prostate, suggesting that this gland is able to perform the aromatization reaction
and it is a feasible local source of estrogen production [39]. Estrogens acts in target cells all over
the body and in addition to sexual organs they influence growth, health and cell activity.
Despite early work of estrogens used as therapy for androgen-resistant prostate cancer, it can
be critical in predisposing prostate cancer.
Estrogens also participate in several pathological changes in the prostate; among the very well
described pathologies is the induction of chronic inflammation [40, 41], squamous metaplasia
reported in several species of mammals [42–44], and human prostate cancer [45].
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There are several pathological complications, including benign and malign proliferative alter-
ations, often aging escalate-associated, that affect prostate gland. So, studies focusing on the
growth regulation and physiology of the prostate are very precious to understand the origin
and progression of these pathologies.
3. Benign prostate hyperplasia (BPH)
Benign prostate hyperplasia (BPH) is a common urological issue that causes prostate enlarge-
ment in men after 40-years-old. It is a noncancerous augmentation of the prostate gland size,
with stromal and glandular epithelial hyperplasia in the transition zone. It is estimated that 50%
of 50 year old, and 75% of 80 year old men could have some lower urinary tract symptom
(LUTS). In such condition the urethra can be partially or totally blocked, resulting in urinary
retention, weak urination stream, incomplete bladder emptying and hesitancy; and so carrying
secondary problems as urinary tract infections, bladder stones and chronic kidney disease,
culminating in kidney failure. The LUTS is reflection of the hormonal changes rising with age,
and resulting in abnormal stromal and epithelial cell proliferation (hyperplasia) in the transition
zone of the prostate. The molecular etiology of these events remains unclear, but few studies
attempt to correlate it to sex steroids hormones [46], also known as gonadocorticoids and
gonadal steroids, that interact with vertebrate androgen and estrogen receptors. It is important
to mention that the BPH is generally not a precursor lesion to a prostate cancer (PCa) condition.
Some animal models studies, including dogs and chimpanzees, have been performed in order to
understand the prostate conditions. Chimpanzees sporadically suffer from age-associated BPH,
and are the closest match to human prostate gland. Throughout the time, dogs are like human
counterpart because they develop BPH containing distinct nodules of hyperplasia with diffuse
areas of compression of the rectum producing constipation, a symptom opposed to the urinary
retention in men [47, 48]. In order to supply these deficiencies, some transgenic animal models
using other normal mammal species were developed. Prostate-specific 15-LOX-2 transgenic
mouse and PPAR∂ knockdown mice naturally develop increased prostate size with age, in
addition to epithelial-hyperplasia, and prostatic intraepithelial neoplasia progression [49, 50].
4. Prostate cancer
Nearly 14 million new cases of cancer occurred worldwide during 2012 [51], generating
around 8.2 million deaths. More than a half of cancer deaths arose in countries of medium or
low human development index (HDI). The four most common types, in this order were lung,
female breast, bowel and PCa. Among malignant neoplasms that affect men, PCa is the most
common, after non-melanoma skin tumors, especially in the male population from the sixth
decade of life. This is a recognized public health problem, since according to data from the
Mortality Information System (MIS), 13,773 deaths were caused by PCa in Brazil in 2013 [52].
Considering the statistics worldwide, PCa prevalence is only beaten by lung cancer in men.
Unlike some types of tumors, the incidence of PCa has increased over the years. There are two
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main factors for this association: the improvement of diagnostic methods and the extended life
expectancy of men over the years; since PCa has slow growth and its incidence is age-
associated, it is very comprehensible the increased detection of this malignant neoplasia lately
in the years. The origin of PCa and the several processes giving direction to PCa carcinogenesis
are still unclear, but often are assumed that several components may influence it, among which
stands out: diet, genetic, hormonal, and environmental factors; all currently being widely
investigated in the literature.
The treatment of PCa can be very controversial because there are many variables, such as the
patient’s age, prostatic specific antigen (PSA) concentrations and the stage of the tumor.
Patients in inoperable conditions, due to age, are treated with hormone therapy or radiation.
The most common hormone therapy for PCa is the androgen deprivation, since the prostate
gland is a highly androgen dependent gland, and because the majority of prostate tumors
originate from androgen-dependent glandular epithelial cells of the prostate [53]. The thera-
pies in use for PCa will be best addressed later in this chapter.
5. Clinical diagnosis and biomarkers for PCa
The diagnosis and follow-up of PCa patients are often difficult because of the absence of
specific markers that could change accordingly to the status of disease, the best therapy, and
the existence of future complications caused by the chosen treatment.
For several decades many researchers joined efforts to study biomarkers of prognosis and
treatment for PCa. Almost 50-years, PSA measurement represented the best marker for PCa.
The primary idea was to substitute the digital rectal examination by PSA screening; neverthe-
less this was not possible despite the low specificity and false positive rate, as it is also
observed in BPH [54]. No significant progress in the use of PSA as a precise biomarker of PCa
was achieved during the past years.
Beyond this scenario, advances in genetic testing for PCa risk and new molecular diagnostic
assays have been designed to improve diagnostic accuracy and treatment decision beyond
prostate-specific antigen (PSA) testing. PSA is a protein of the kallikrein family synthesized in
the prostatic epithelium and secreted in the seminal fluid. From its discovery in 1970 to the
present day, it is a diagnostic tool used as a tumor marker for early diagnosis, treatment and
monitoring of patients with neoplasia in conjunction with the rectal examination. However,
many studies have questioned the use of this biomarker for a diagnosis, due to the exponential
increase in the diagnosis of PCa and, consequently, the increase of unnecessary hormonal,
radiotherapeutic, chemotherapeutic and surgical treatments such as radical prostatectomy
[55, 56]. PSA evaluation is performed by its measurement in serum using immunoassay (34
kDa). Normal values vary according to the method used. In most tests, values of up to 2.5 ng/
mL are allowed as normal. If this value is higher, it is indicated to request the dosage of
fractionated PSA, which relates total PSA to free PSA (fPSA). The result is expected to be equal
to or greater than 20%; if it is lower, there is a probability that it is a PCa [57]. However, this test
does not have 100% of specificity or sensitivity, insofar as there is PCa whose PSA is not
altered, and there are other transient factors that can raise serum PSA levels, such as prostatitis
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[58], benign prostatic hyperplasia [59], prostatic biopsies [60] and trauma, due to prostatic cell
lysis releasing PSA into the bloodstream [61].
Despite results enhancing detection at earlier stage and decreasing the number of metastatic
patients, the use of prostate-specific antigen (PSA) to detect PCa has low specificity, unneces-
sary biopsies and frequently mistaken diagnoses. Also, PCa has various features so prognosis
following diagnosis is greatly variable. Hence, there is a requirement for new prognostic bio-
markers, particularly to differentiate between inactive and aggressive forms of the disease, to
improve clinical management of PCa patients. Research continues into finding additional
markers that may allow this goal to be attained.
In order to improve the specificity of PSA as a tumor biomarker, tests called PHI (Prostatic
Health Index), that predicts the risk of having PCa and 4 K score™ (predicts the risk of having
high-risk of PCa) were launched on the American and European markets [62]. 4 K score™ blood
test combines 4 prostatic biomarkers (total PSA, fPSA, intact PSA, and human kallekrein 2(hK2))
with the age of the patient, the digital rectal exam (DRE) findings (presence of a nodule or not),
and the result of previous biopsies [63]. The higher the score, the greater the probability of
finding tumor cells in a biopsy (Gleason ≥ 7). This test combination is interesting because it does
not allow unnecessary biopsies to be performed, whereas post-operative, as well as any surgery,
has risks and can lead to future complications for the patient, affecting his quality of life.
Another non-invasive test available is the ExoDxTM Prostate (IntelliScore) Test18, which,
through urinalysis, assesses the risk of developing invasive PCa, and thereby target the best
treatment by molecular analysis of three specific genes in exosome and microvesic RNAs
released by tumor cells, called extracellular vesicles (further discussed in this chapter) [64].
These related genes (ERG, PCA3 and SPDEF) are most commonly related to tumor progression
and, consequently, its aggressiveness and invasion [65].
It is important to note that these tests are not accessible to the entire population, either because
of the high cost of the technology, or because some countries have still not approved it. Thus,
the main diagnostic method used nowadays for the screening and detection of the PCa
remains PSA testing and rectal examination (DRE). If the results of these exams are altered, a
biopsy is necessary to confirm the diagnosis, and determine the aggressiveness and prognosis
of the cancer. This is done by histological analysis of the biopsied tissue, following classifica-
tion according to the Gleason Scale. This system consists of the sum of 2 values that represent
the degree of the tumor, and that determine the dominant cellular pattern and the most
frequent cellular pattern, respectively. Tumor grades range from 1 to 5, the former representing
more differentiated and prostate restricted tumors, while the latter represents totally undiffer-
entiated tumors that have normally infiltrated the glandular stoma. The score, therefore,
ranges from 2 (1 + 1) to 10 (5 + 5), and values below 4 on the Gleason Scale represent a well
differentiated PCa; between 5 and 7, an intermediate PCa; and between 8 and 10, advanced
PCa [66]. The determination of the degree and stage of cancer allows classification into high,
intermediate and low risk categories.
The clinical picture of castrated-resistant prostate cancer (CRPC) is quite heterogeneous, rang-
ing from the asymptomatic increase in the PSA indices to the distant metastasis (commonly
bone metastasis), with an important impairment of the patient’s quality of life [66]. This is a
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reflection of the complexity and diversity of biomolecular alterations already found in biop-
sies. Tumor progression is related to a number of genetic changes that can affect AR, signaling
cascades, apoptosis mechanisms and cell regulation, or, as in many cases, a combination of all
of them [67].
Biomolecular techniques, such as fluorescent in situ hybridization (FISH) and Microarray, for
example, have identified a variety of key factors genes, oncogenes and tumor suppressor
genes, related to the development and progression of PCa [68, 69]. The use of molecular
techniques also allowed the identification of some genes related to the suppressive function of
metastasis, opening a new perspective for researching the phenomenon of tumor invasion to
other tissues and, with that, to identify and elucidate new indicators of prognosis, or even PCa
target therapies. As example, some studies have focused attention on the CDH1 gene and its
protein expression, located on chromosome 16q22, which encodes the E-cadherin, a glycopro-
tein responsible for cell-cell adhesion, an important cellular function that prevents EMT in
tumor progression [70].
The Metastatic prostate adenocarcinoma (metPA) is diagnosed by immunohistochemistry.
Nowadays very promising biomarkers have been used to determine prostatic origin of metPA,
such as prostate specific membrane antigen (PSMA) and NKX3.1 [71]. PSMA is a type II
membrane protein not secreted and is expressed in all forms of prostate tissue, but it is
expressed at high levels on malignant prostate cells with limited extraprostatic expression
[72]. Many approaches to target PSMA include DNA-based vaccines, as well as passive
administration of monoclonal antibodies (PSMA-mAb), including 7E11.C5.3, that has already
been approved by USA FDA (Food and Drug Administration); the medication is commercially
available as ProstaScint® [72, 73].
Compared to PSA, PSMA is upregulated with androgen deprivation, and its expression was
correlated with cancer aggressiveness and poor prognosis, while PSA decreases with androgen
deprivation [72]. PSMA was also evaluated in PCa using PETmolecular imaging system. After
all, PSMA is not specific only to prostate gland; it is expressed in other normal tissues (such as
salivary glands, duodenal mucosa, renal tubular cells, and neuroendocrine cells in the colon),
and in malignant cells (renal cell carcinomas, colon carcinomas, and endothelial cells that
surround or are into the tumors) [74].
Although multiple independent studies sought to demonstrate evidence that genetic variations
may be independent predictors of PCa risk in addition to family history and serum PSA levels,
the challenge in the years to come will be to introduce these new gene-based diagnostic and
prognostic tests in algorithms integrating the other known risk factors including age, ethnicity,
family history and PSA level to better tailor diagnostic and therapeutic strategies for PCa.
5.1. The extracellular vesicles (exosomes) and PCa: beyond classical biomarkers
Several studies have related to novel PCa biomarkers that can precisely detect, and treat, types
of aggressive cancer by headlining circulating tumor cells (CTCs) and circulating extracellular
vesicles (EVs) (Figure 1). Notably, EVs are released by almost all the cells, and brings lots of
molecular information. The study based on EVs provides lots of information about its content,
Pathophysiology - Altered Physiological States190
Figure 1. Representative TEM images of exosomes derived from (a) C42 PCa cell line, (b) LNCaP xenograft serum and (c)
patient plasma by ultracentrifugation method. Exosomes were negatively stained with 2% uracyl acetate after removal of
moisture. Arrows indicate cup-shaped structures which are identified as exosomes (30–100 nm in diameter). From:
Kharmate et al. [86]. Online available at: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0154967.
Figure 2. Schematic representation of possible role of EGFR-exosomes in cancer progression. Ligand binding induces rapid
activation and internalization of EGFR and endocytosis. Whether EGFR escapes lysosomal degradation and is released
extracellularly via exosomes is unknown. The transfer of EGFR via exosomes may significantly alter the tumor microen-
vironment and could be relevant to progression of an aggressive PCa. From: Kharmate et al. [86]. Online available at:
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0154967.
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such as: lipids, proteins, nucleic acids and metabolites [75, 76]. All of each can be isolated in
small volumes from body fluids, just by using some steps of ultracentrifugation, as a non-
invasive method to monitor disease progression, and are proposed to function as tumor-
specific molecular signatures. They are small structures (50–150 nm) that carry genetic and/or
nongenetic materials from tumor cells. Recent study analyzed the presence of CD9 and CD63
(a housekeeping exosome marker) positive EVs, demonstrating that patients with metastatic
cancer and detectable CTCs have higher CD9 detectable in plasma [77]. The CD9 positive EVs
were found higher in plasma of PCa patients compared to HPB patients, and were related to
paracrine signaling that contributes to PCa progression [77]. In silico reanalysis of genes
involved in vesicular trafficking demonstrated that the expression of required well-known
endosomal sorting complexes, such as RAB27A, RAB27B and VPS36, are downregulated in
patients with advanced PCa [78].
Other studies suggest possible micro-RNAs roles in PCa [79] due to their recruitment to EVs
present in various human body fluids; they are miR-2909 and miR-615-3p, which was detected
in urinary-exosomal of PCa patients [80, 81]. Also EVs was useful to monitor the response to
radiation therapy, in the search for a personalized treatment according to different profiling
levels [82].
Table 1. Biomarkers in PCa detection and prognosis.
Pathophysiology - Altered Physiological States192
Additionally to androgens (as described in Section 3), prostate physiology is, in part, regu-
lated by the epidermal growth factor (EGF), whose action is mediated by its receptor
(EGFR). EGFR is one of the mediators of cell proliferation, and its overexpression has been
associated with aggressiveness and invasion of PCa. It has been described and identified as
an important anti-PCa target, and some inhibitors of EGFR were tested with limited effec-
tiveness in prostate cancer patients; they are Gefitinib, Lapatinib, and Erlotinib [83–85].
Recently, EGFR was also observed in EVs (Figure 2) of PCa patients [86].
Previous studies have demonstrated that PSA can be detectable in plasma and urine derived
EV’s [87]. Logozzi et al. [88] demonstrated that an acid microenvironment (such as the tumor
microenvironment), functions as a key factor for the exosomal releasing, and determines the
quality and quantity of released vesicles, including the ones containing PSA, an enzyme that
needs an acidic microenvironment for full activation, in PCa.
Figure 3. The prostate specific antigen (PSA) remains the most used biomarker in the management of early prostate cancer
(PCa), in spite of the problems related to false positive results and overdiagnosis. New biomarkers have been proposed in
recent years with the aim of increasing specificity and distinguishing aggressive from non-aggressive PCa. The emerging
role of the prostate health index and the 4Kscore: both are blood-based tests related to the aggressiveness of the tumor,
which provide the risk of suffering PCa and avoiding negative biopsies. Furthermore, the use of urine has emerged as a
non-invasive way to identify new biomarkers in recent years, including the PCA3 and TMPRSS2: ERG fusion gene.
Available results showed PCA3 score usefulness to decide the repetition of biopsy in patients with a previous negative
result, although its relationship with the aggressiveness of the tumor is controversial. More recently, aberrant the
microRNA expression in PCa has been reported by different authors. The utility of circulating and urinary microRNAs in
the detection and prognosis of PCa has also been explored. Although several of these new biomarkers have been
recommended by different guidelines, large prospective and comparative studies are necessary to establish their value in
PCa detection and prognosis. From: Filella and Foj [69]. Online available at: http://www.mdpi.com/1422-0067/17/11/1784.
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To summarize, in recent years, many new promising PCa biomarkers have been identified
(Table 1) (Figure 3), and found to be associated with tumor aggressiveness. Multiplied studies
showed the utility of the PHI, the 4Kscore™ and the PCA3 score to reduce the number of
unnecessary prostate biopsies in PSA tested men. Actually, these biomarkers have been
recommended for different guidelines. Still, large prospective studies, avoiding bias due to
selection of patients according to PSA serum levels, are necessary to compare the value of these
biomarkers. Also, new efforts are necessary to standardize the methodology for the measure-
ment of exosomal and non-exosomal miRNAs, in order to analyze accurately their usefulness
in the management of patients with early PCa. Finally, the combined role of these biomarkers
together with magnetic resonance imaging data should be elucidated [89].
Adapted from: Filella and Foj [69]. (*Recommended by the National Comprehensive Cancer
Network).
6. Treatment modalities for PCa
PCa treatment is variable, and it is chosen according to the staging of the cancer and, mainly,
according to the patient’s own preference. Since this type of cancer has slow growth, the
presence of low-risk groups, where tumor is diagnosed still in situ, is indicative of an active
surveillance treatment in which the patient only accompanies the tumor through regular PSA
testing, and digital touch every 3–6 months [90]. During this follow-up period, if the existence
of a tumor progression is observed, radiotherapy or surgery is indicated by total removal of
the prostate gland (radical prostatectomy).
Radical prostatectomy may be the first choice of the patient who opts for complete removal of
the gland, by caution of future metastasis. It is an effective procedure, however, just like any
surgical procedure, there may be complications and compromise the patient’s quality of life.
For this procedure, the most common complications are the urinary incontinence, erectile
dysfunction, and inguinal hernia; anyhow, the prognosis tends to be positive and long-lasting
[91]. Nonetheless, some tumors may recur over time even after radical prostatectomy. In such
cases, it is important to evaluate whether the recurrence was local or occurred at a distance
(lymph nodes or other organs, such as liver, bone, or lung).
Hormone therapy is usually used in patients with lymph node involvement or distant metasta-
sis. It consists of reducing androgen concentrations to the level of castration. This can be done by
surgical method through bilateral orchiectomy, or through drugs that act on the androgen
receptor (AR) pathways; the latter being more commonly used nowadays. At first, hormone
deprivation therapy has great effects on the control of advanced PCa. However, it is known that
part of the cases evolves to the state of CRPC. The mechanisms responsible for progression of
tumor growth, despite hormonal blockade, have not been fully elucidated yet. Current studies
have shown that molecular changes in the androgen receptor (AR) are related to such progres-
sion. Among these changes, it is relevant to mention the overexpression of AR, mutations in the
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AR gene that allow its activation by other endogenous steroids, increased production of growth
factors activating AR even in the absence of androgen, changes in co-regulatory proteins and
upregulation of enzymes related to androgen synthesis [92].
There are two drug lines for hormone therapy; the first line accounts for the central blockers
that constitute the agonists of gonadotrophin-releasing hormone (GnRH agonists), and the
peripheral androgen receptor blockers. Usually they are used in a comminuted way, since the
central blockers, for example, Leuprolide (Lupron) and Gosserelin Acetate (Zoladex), acts
through the interruption of the pituitary feedback mechanism, inhibiting LH realizing by the
pituitary gland, and leading to a decreased testoterone production [63]. However, because
these drugs initially boosted testosterone production, the combination with peripheral andro-
gen receptor blockers, such as Bicalutamide (Casodex), Flutamide (Flutamide) and Androcur
(Androcur), shall be indicated due to their binding capacity to the ARs in a way that inhibits
androgenic stimulation, deactivating their genetic expression [93].
The second line of therapy is most commonly used when PCa is resistant to the first-line
hormonal therapies stage. Abiraterone Acetate (Zytiga) is a drug that primarily acts on the
adrenal gland through the inhibition of the 17α-hydroxylase/C17, 20-lyase (CYP17) enzyme,
essential for androgen biosynthesis in tissues [94, 95]. Enzalutamide (Xtandi) is another drug
of this therapeutic line that works by inhibiting androgen receptors, their signaling pathways,
and is able to act on anti-androgen-resistant tumor cells.
It is important to emphasize that hormonal therapy is a palliative treatment, in that it acts to
contain the progression of advanced PCa, and not its elimination. In this context, given the
scarcity of effective treatments for these types of tumors, it is promising to still search for new
biomarkers capable of not only diagnosing PCa early, but also being able to evaluate its
aggressiveness and prognosis.
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